1. MAIA
  2. Topics
  3. Recovery from depression
  4. References

Recovery from depression

Therapeutic Brief

  1. Zhao Y, Yang L, Sahakian BJ, Langley C, Zhang W, Kuo K, et al. The brain structure, immunometabolic and genetic mechanisms underlying the association between lifestyle and depression. Nature Mental Health. 2023;1(10):736-50.
  2. Sarris J, Thomson R, Hargraves F, Eaton M, de Manincor M, Veronese N, et al. Multiple lifestyle factors and depressed mood: a cross-sectional and longitudinal analysis of the UK Biobank (N = 84,860). BMC Medicine. 2020;18(1):354.
  3. Cao Z, Min J, Xiang YT, Wang X, Xu C. Healthy lifestyle and the risk of depression recurrence requiring hospitalisation and mortality among adults with pre-existing depression: a prospective cohort study. BMJ Ment Health. 2024;27(1).
  4. Horowitz MA, Framer A, Hengartner MP, Sørensen A, Taylor D. Estimating Risk of Antidepressant Withdrawal from a Review of Published Data. CNS Drugs. 2023;37(2):143-57.
  5. Horowitz MA, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Advances. 2022;28(5):297-311.
  6. Zhang M-M, Tan X, Zheng Y-B, Zeng N, Li Z, Horowitz MA, et al. Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review. Molecular Psychiatry. 2024.
  7. Malhi GS, Bell E, Bassett D, Boyce P, Bryant R, Hazell P, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2021;55(1):7-117.
  8. Zimmerman M, Balling C, Chelminski I, Dalrymple K. Understanding the severity of depression: Which symptoms of depression are the best indicators of depression severity? Comprehensive Psychiatry. 2018;87:84-8.
  9. Kirkbride JB, Anglin DM, Colman I, Dykxhoorn J, Jones PB, Patalay P, et al. The social determinants of mental health and disorder: evidence, prevention and recommendations. World Psychiatry. 2024;23(1):58-90.
  10. Mohammed M, Moles R, Chen TF. Medication-related burden and patients' lived experience with medicine: a systematic revidw and metasythesis of qualitative studies. BMJ Open. 2016;6: e010035.doi:10.1136/bmjopen-2015-010035.
  11. Anderson J, Galvez V, Loo C, Mitchell P. Adult depression. A step-by-step guide to treatment. Medicine Today. 2015;16(11):16-24.
  12. Malhhi G, Bassett D, Boyce P, Bryant R, Fitzgerald P, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian and New Zealand Journal of Psychiatry. 2015;49(12):1087-206.
  13. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. 12 Edition. Oxford, United Kingdom: Wiley Blackwell; 2015.
  14. Guidelines N. Depression in adults: recognition and management. Available at: https://www.nice.org.uk/guidance/cg90/resources/depression-in-adults-recognition-and-management-975742636741 [Accessed December 2015]. 2009.
  15. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry. 2013;14(5):334-85.
  16. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. Jama. 2010;303(1):47-53.
  17. Australian Institute of Health Welfare. Mental health-related prescriptions 2023 2023 [Available from: https://www.aihw.gov.au/mental-health/topic-areas/mental-health-prescriptions.
  18. de Oliveira Costa J GM, Litchfield M, Pearson S-A. Antidepressant use among Australians between 2015 to 2023: An updated analysis including the post-pandemic era. Centre of Research Excellence in Medicines Intelligence, UNSW. 2024.
  19. Kjosavik SR, Gillam MH, Roughead EE. Average duration of treatment with antidepressants among concession card holders in Australia. Aust N Z J Psychiatry. 2016;50(12):1180-5.
  20. Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. March 2017. Available at: http://online.tg.org.au/ip/desktop/index.htm [Accessed July 2017].
  21. Lu CY, Roughead E. New users of antidepressant medications: first episode duration and predictors of discontinuation. Eur J Clin Pharmacol. 2012;68(1):65-71.
  22. DeRubeis RJ, Zajecka J, Shelton RC, Amsterdam JD, Fawcett J, Xu C, et al. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020;77(3):237-45.
  23. Guidi J, Fava GA. Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(3):261-9.
  24. Breedvelt JJF, Warren FC, Segal Z, Kuyken W, Bockting CL. Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression: An Individual Participant Data Meta-analysis. JAMA Psychiatry. 2021;78(8):868-75.
  25. Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. J Psychiatr Res. 2016;77:42-51.
  26. Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. The <em>Lancet Psychiatry</em> Commission: a blueprint for protecting physical health in people with mental illness. The Lancet Psychiatry. 2019;6(8):675-712.
  27. Horowitz M TD. The Maudsley Deprescribing Guidelines. Antidepresants, Benzodiazapines, Gabapentanoids, and Z-drugs 1 ed: John Wiley & Sons Ltd2024. 57-292 p.
  28. Bansal N, Hudda M, Kessler D, Payne RA, Smith DJ, Wiles N. Antidepressant use and risk of adverse outcomes: population-based cohort study. BJPsych Open. 2022;8(5):e164.
  29. Cartwright C, Gibson K, Read J, Cowan O, Dehar T. Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Prefer Adherence. 2016;10:1401-7.
  30. Anderson C, Kirkpatrick S, Ridge D, Kokanovic R, Tanner C. Starting antidepressant use: a qualitative synthesis of UK and Australian data. BMJ Open. 2015; 5: e008636.
  31. Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203.
  32. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav. 2019;97:111-21.
  33. Duffy L, Clarke CS, Lewis G, Marston L, Freemantle N, Gilbody S, et al. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT. Health Technol Assess. 2021;25(69):1-62.
  34. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry. 2024;11(7):526-35.
  35. Gastaldon C, Schoretsanitis G, Arzenton E, Raschi E, Papola D, Ostuzzi G, et al. Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database. Drug Saf. 2022;45(12):1539-49.
  36. Van Leeuwen E, van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AI, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev. 2021;4(4):Cd013495.
  37. Atkins B, Maden M, Birt L, Tromans S, Swithenbank Z, Kersey OR, et al. Primary care healthcare professionals supporting patients to discontinue antidepressants: A scoping review of barriers, enablers and interventions. Research in Social and Administrative Pharmacy. 2025;21(6):431-43.
  38. Gøtzsche PC, Demasi M. Interventions to help patients withdraw from depression drugs: A systematic review. Int J Risk Saf Med. 2024;35(2):103-16.
  39. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538-46.